Silence’s siRNA therapy maintains Lp(a) lowering in cardiovascular study

### Title
Silence Therapeutics' siRNA Therapy Demonstrates Sustained Lipoprotein(a) Reduction in Phase 2 Study for Cardiovascular Disease
### Keywords
- Silence Therapeutics
- siRNA therapy
- Lipoprotein(a) reduction
- Cardiovascular disease
- Phase 2 study
### Key Facts
1. Positive Phase 2 Results: Silence Therapeutics announced positive topline 48-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran (SLN360) in patients with elevated lipoprotein(a) (Lp(a)) levels, demonstrating highly significant and sustained reductions in Lp(a) to week 48.
2. Lp(a) Reduction: The study showed a median percentage reduction in Lp(a) of 90% or greater for both doses at week 36, consistent with phase 1 results.
3. Cardiovascular Risk: Elevated Lp(a) levels are a key genetic risk factor for cardiovascular disease, affecting up to 20% of the world’s population.
4. siRNA Mechanism: SLN360 is a short interfering RNA (siRNA) designed to lower the body’s production of Lp(a) by targeting messenger RNA transcribed from the LPA gene.
5. Future Development: The company plans to advance zerlasiran into phase 3 based on these positive results.